Neurology · PANCE / PANRE

Diabetic Peripheral Neuropathy

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Most common complication of diabetes; distal symmetric stocking-glove sensorimotor neuropathy.

Also known as: diabetic neuropathy, diabetic peripheral neuropathy, DPN, distal symmetric polyneuropathy, DSPN

Overview

Distal symmetric, length-dependent, predominantly sensory polyneuropathy that develops as a complication of long-standing diabetes mellitus, after exclusion of other causes. Encompasses several syndromes; distal symmetric polyneuropathy (DSPN) is the most common form.

Epidemiology

Prevalence ~30-50% of patients with diabetes (rises with disease duration); ~10-20% have painful diabetic neuropathy. The most common cause of peripheral neuropathy in the US. Leading cause of non-traumatic lower-extremity amputation.

Try two board-style Diabetic Peripheral Neuropathy questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1NeurologyEasy
A 60-year-old male with type 2 diabetes mellitus (T2DM) has right foot numbness, tingling, and burning pain that is worse at night. Sensation to monofilament is absent at the plantar surface of the great toe bilaterally. Nerve conduction studies show reduced sensory amplitudes and mildly slowed conduction velocities in bilateral lower extremities in a length-dependent pattern. Which of the following is the most likely diagnosis?
  • AVitamin B12 deficiency neuropathy
  • BPeripheral arterial disease
  • CDiabetic peripheral neuropathy
  • DLumbar radiculopathy
Reveal answer & full explanation
Correct answer: C — Diabetic peripheral neuropathy
  • AVitamin B12 deficiency neuropathy
  • BPeripheral arterial disease
  • CDiabetic peripheral neuropathy✓
  • DLumbar radiculopathy

Why Diabetic peripheral neuropathy is correct

  • Diabetic peripheral neuropathy (DPN) is the most common form of peripheral neuropathy worldwide.
  • Presents as a length-dependent polyneuropathy with stocking-glove distribution, starting in the feet and ascending symmetrically — matching this patient's bilateral plantar foot findings.
  • Nerve conduction studies (NCS) show reduced sensory amplitudes (axonal loss) with mildly slowed conduction velocities, as seen here.

Why the others are wrong

  • A) Vitamin B12 deficiency neuropathy — also causes length-dependent neuropathy but typically includes posterior column signs (loss of vibration and proprioception) and may show macrocytosis; T2DM on metformin is a risk factor, but NCS pattern and clinical context favor DPN here.
  • B) Peripheral arterial disease — causes claudication and reduced/absent pulses, not the sensory neuropathy pattern with abnormal NCS described.
  • D) Lumbar radiculopathy — causes a dermatomal (not stocking-glove) distribution and is unilateral or asymmetric, not bilateral length-dependent.

Additional high-yield points

  • Management: glycemic optimization slows progression.
  • Neuropathic pain pharmacotherapy: duloxetine, pregabalin, gabapentin, or amitriptyline.
  • Topical capsaicin or lidocaine patches for localized pain.
  • Avoid chronic opioids for diabetic peripheral neuropathy.
Question 2NeurologyMedium
A 62-year-old man with diabetes has burning bilateral foot pain and decreased vibration sense. Which of the following best explains this condition?
  • APeripheral arterial occlusive disease
  • BPosterior column degeneration from B12 deficiency
  • CLength-dependent axonal peripheral nerve injury
  • DLumbosacral nerve root compression
Reveal answer & full explanation
Correct answer: C — Length-dependent axonal peripheral nerve injury
  • APeripheral arterial occlusive disease
  • BPosterior column degeneration from B12 deficiency
  • CLength-dependent axonal peripheral nerve injury✓
  • DLumbosacral nerve root compression

Why Length-dependent axonal peripheral nerve injury is correct

  • Diabetic peripheral neuropathy is a distal symmetric, length-dependent polyneuropathy.
  • Chronic hyperglycemia causes metabolic and microvascular damage that strikes the longest axons first, hence the feet.
  • Symmetric burning pain with reduced vibration in a stocking pattern is the classic signature.

Why the others are wrong

  • Lumbosacral nerve root compression — Radiculopathy causes asymmetric, dermatomal pain with focal weakness, not a symmetric stocking distribution (asymmetric-pattern trap).
  • Posterior column degeneration from B12 deficiency — B12 deficiency also impairs vibration but typically adds brisk reflexes and a positive Romberg, and is a separate cause to test for, not the default in diabetes (overlapping-sensory trap).
  • Peripheral arterial occlusive disease — PAD causes claudication, cool pulseless feet, and ischemic rest pain rather than a burning sensory neuropathy with preserved warmth (vascular-vs-neuropathic trap).
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Diabetic Peripheral Neuropathy outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Duration of diabetes
  • Poor glycemic control (higher A1c)
  • Older age
  • Hypertension, dyslipidemia (especially elevated triglycerides), obesity
  • Smoking and alcohol use
  • Type 1 diabetes (autoimmune component) and type 2 diabetes
  • Tall stature (longer axons)
  • Vitamin B12 deficiency (often comorbid; metformin exacerbates)
  • Genetic susceptibility

Pathophysiology

Multifactorial: chronic hyperglycemia leads to polyol pathway flux (sorbitol accumulation), advanced glycation end-product (AGE) formation, oxidative stress, protein kinase C activation, mitochondrial dysfunction, and microvascular insufficiency of the vasa nervorum. Length-dependent dying-back axonopathy preferentially affects long, small-fiber (unmyelinated C, thinly myelinated Aδ) sensory and autonomic axons first, then larger myelinated fibers; longest axons (toes, feet) are affected first.

Clinical presentation

Symptoms

  • Insidious onset, stocking-then-glove progression
  • Sensory: numbness, tingling, burning, prickling, allodynia (pain from non-painful stimuli), hyperalgesia, lancinating pain
  • Symptoms often worse at night
  • Loss of protective sensation predisposes to unnoticed foot injury, ulceration, and Charcot arthropathy
  • Motor: weakness late (intrinsic foot, then distal lower-extremity), foot drop occasional
  • Autonomic: orthostatic hypotension, resting tachycardia, gastroparesis, neurogenic bladder, erectile dysfunction, gustatory sweating, anhidrosis of feet (predisposes to dry, cracked skin)
  • Atypical syndromes: diabetic amyotrophy (proximal asymmetric leg weakness with pain), cranial mononeuropathies (CN III with pupil sparing, CN VI), thoracic radiculoneuropathy, treatment-induced neuropathy after rapid glucose lowering

Signs / physical exam

  • Stocking-distribution decreased pinprick, light touch, vibration (128-Hz tuning fork), and proprioception
  • Diminished or absent ankle reflexes (knee reflexes usually preserved early)
  • 10-g Semmes-Weinstein monofilament insensate at one or more sites — high sensitivity for risk of foot ulceration
  • Intrinsic foot muscle wasting, hammer/claw toes, pes cavus deformity (late)
  • Romberg may be positive (large-fiber involvement)
  • Look for foot ulcers, fissures, calluses, Charcot deformity
  • Autonomic: postural BP drop, resting tachycardia, abnormal heart rate variability

Classic findings

Symmetric stocking-distribution sensory loss with absent ankle reflexes in a patient with diabetes.

Differential diagnosis

  • Vitamin B12 deficiency — Sensory ataxia (loss of proprioception, positive Romberg), macrocytic anemia, cognitive changes; check B12, MMA, homocysteine; often coexists with DPN, especially on metformin
  • Alcohol-related neuropathy — History of heavy alcohol use, nutritional deficiencies (thiamine, B6, folate)
  • Chemotherapy-induced peripheral neuropathy — Platinums, taxanes, vincristine, bortezomib; temporal relation to chemotherapy
  • Hypothyroidism — Cold intolerance, weight gain, constipation, dry skin; elevated TSH
  • Chronic kidney disease (uremic neuropathy) — Advanced renal failure; improves with dialysis or transplant
  • Monoclonal gammopathy / amyloidosis — SPEP/UPEP, immunofixation, free light chains; check in older patients with rapidly progressive or painful neuropathy
  • Vasculitis (mononeuritis multiplex) — Multifocal, asymmetric, often painful; constitutional symptoms; nerve biopsy if needed
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) — Symmetric proximal AND distal weakness, areflexia, elevated CSF protein; treat with IVIG, steroids, plasma exchange — distinct from DPN and IMPORTANT not to miss
  • Hereditary neuropathy (Charcot-Marie-Tooth) — Family history, foot deformity (pes cavus, hammer toes), early onset
  • Heavy metal toxicity (lead, arsenic, mercury), HIV, hepatitis C, Lyme disease, paraneoplastic — History clues, targeted serology and toxicology

Diagnostic workup

Diagnostic criteria

ADA/Toronto Consensus: typical DPN = patient with diabetes and distal symmetric polyneuropathy attributable to diabetes after exclusion of other causes; supported by characteristic signs/symptoms and confirmed by nerve conduction studies (in atypical or research settings).

Labs

  • Confirm diabetes and assess control: fasting glucose, A1c
  • Exclude common alternative or coexisting causes: CBC, BMP, TSH, vitamin B12 (with MMA if borderline), serum/urine protein electrophoresis with immunofixation (especially in older patients or atypical features), LFTs
  • Consider HIV, hepatitis C, Lyme, heavy metals, paraneoplastic antibodies if clinical suspicion
  • Lipid panel (cardiovascular risk and triglyceride-related neuropathy)

Imaging

  • Electrodiagnostic studies (NCS/EMG): not routinely required for typical DPN, but indicated for atypical features (asymmetric, predominantly motor, rapidly progressive, proximal involvement, areflexia, family history) to distinguish from CIDP, hereditary, or compressive neuropathies
  • Foot exam with monofilament and tuning fork at least annually in all patients with diabetes (ADA/IWGDF recommendation)
  • Skin biopsy for intraepidermal nerve fiber density and corneal confocal microscopy — research/specialty tools for small-fiber neuropathy

Diagnostic algorithm

Drug ClassExamplesCommon Adverse EffectsNotes
GabapentinoidPregabalin, gabapentinSedation, dizziness, edema, weight gainPregabalin FDA-approved; renal dose adjustment
SNRIDuloxetine, venlafaxineNausea, dry mouth, somnolence, BP riseDuloxetine FDA-approved; caution with hepatic disease
TCAAmitriptyline, nortriptylineAnticholinergic, QT prolongation, orthostasisAvoid in elderly and cardiac disease; nortriptyline better tolerated
Opioid (atypical)Tapentadol ER, tramadolSedation, constipation, dependence, serotonin syndrome (tramadol + SNRI/SSRI)Tapentadol FDA-approved; opioids generally avoided long-term
TopicalCapsaicin 8% patch, lidocaine 5%Local burning, erythema (capsaicin)Capsaicin 8% FDA-approved; in-office application
Neuromodulation10-kHz spinal cord stimulationProcedural risks, lead migrationFDA-approved 2021 for refractory painful DPN
Pharmacologic and neuromodulatory options for painful diabetic peripheral neuropathy.

Treatment

First-line

  • Glycemic control — strongest evidence for delaying progression in type 1 (DCCT/EDIC); more modest effect in type 2 (UKPDS, ACCORD). Avoid hypoglycemia in autonomic neuropathy.
  • Cardiovascular risk factor management: BP control (<130/80), statin therapy, smoking cessation, weight loss
  • Foot care education: daily inspection, well-fitting footwear, no barefoot walking, podiatry care; annual comprehensive foot exam by clinician; offload pressure points
  • Symptomatic treatment of painful DPN — FDA-approved or first-line agents (ADA 2022, AAN):
  • • Pregabalin 150-600 mg/day in divided doses (FDA-approved; sedation, edema, weight gain)
  • • Duloxetine 60-120 mg/day (FDA-approved; nausea, dry mouth, somnolence, hepatic caution)
  • • Gabapentin 900-3600 mg/day in divided doses (off-label but widely used; sedation, dizziness, edema)
  • • Tricyclic antidepressant — amitriptyline, nortriptyline 25-100 mg qhs (anticholinergic side effects, QT prolongation, orthostasis — caution in elderly and cardiac disease)
  • • Tapentadol ER (FDA-approved) — opioid; consider only after non-opioid options exhausted
  • Topical agents: capsaicin 8% patch (FDA-approved), topical lidocaine 5%

Second-line / adjunct

  • Combination therapy if monotherapy insufficient (e.g., gabapentinoid + duloxetine, gabapentinoid + TCA)
  • Tramadol short-term; avoid chronic opioids if possible (limited efficacy, dependence/overdose risk)
  • Spinal cord stimulation (10-kHz high-frequency) — refractory painful DPN; FDA-approved 2021
  • Treat autonomic complications: orthostatic hypotension (compression stockings, midodrine, droxidopa, fludrocortisone), gastroparesis (small frequent meals, metoclopramide — limit duration; prokinetics; gastric pacing), neurogenic bladder (timed voiding, intermittent catheterization), erectile dysfunction (PDE5 inhibitors)
  • Address vitamin B12 deficiency (oral 1000 mcg/day or parenteral); ADA recommends periodic B12 screening in patients on chronic metformin
  • Aldose reductase inhibitors and alpha-lipoic acid — modest evidence; not FDA-approved in the US
  • Multidisciplinary diabetes care including podiatry, vascular surgery, and wound care for at-risk feet
  • Smoking cessation counseling, alcohol reduction

Complications

  • Foot ulceration and infection
  • Charcot neuroarthropathy (painless midfoot collapse with bony destruction; needs prompt offloading and immobilization)
  • Lower-extremity amputation (DPN is the leading cause of non-traumatic amputation)
  • Falls and fractures from sensory ataxia and proprioceptive loss
  • Cardiovascular autonomic neuropathy → silent ischemia, sudden cardiac death, exercise intolerance
  • Gastroparesis with poor glycemic control, weight loss, bezoar formation, esophagitis
  • Neurogenic bladder → UTIs, urinary retention
  • Erectile dysfunction and orgasmic dysfunction
  • Hypoglycemia unawareness from autonomic failure
  • Chronic pain → depression, sleep disturbance, opioid dependence

PANCE pearls

  • Always exclude other causes of neuropathy before attributing all symptoms to diabetes — B12 deficiency is the most common reversible coexisting cause (and is worsened by metformin).
  • Asymmetric, predominantly motor, or rapidly progressive neuropathy should raise concern for CIDP, vasculitis, or paraneoplastic causes — order NCS/EMG and additional workup; CIDP is treatable (IVIG, steroids).
  • Annual foot exam with 10-g monofilament + tuning fork is the highest-yield screening intervention to prevent amputation.
  • Glycemic control is most effective at preventing neuropathy progression in type 1 DM; effect is more modest in type 2.
  • Treatment-induced neuropathy of diabetes ('insulin neuritis') can occur with rapid A1c reduction — counsel patients before intensifying therapy.
  • Charcot foot may mimic cellulitis (red, warm, swollen, painless) — recognize and offload immediately; missed Charcot leads to amputation.
  • Cardiovascular autonomic neuropathy (resting tachycardia, blunted heart rate variability, orthostasis) is associated with increased mortality — consider beta-blocker cautiously.
  • Avoid combination of tramadol with SSRIs/SNRIs (serotonin syndrome) and watch for QT prolongation with TCAs and methadone.
  • Painful DPN responds to gabapentinoids, duloxetine, or TCAs — choose based on comorbidities (renal function, mood, cardiac status).

References

  • ADA 2022 — Diabetic Neuropathy: A Position Statement by the American Diabetes Association (Pop-Busui et al., Diabetes Care 2017; updates within Standards of Care)
  • AAN 2022 — Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update (Price et al., Neurology 2022)
  • Toronto Consensus — Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments (Tesfaye et al., Diabetes Care 2010)
  • DCCT/EDIC — Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy (DCCT Research Group, Ann Intern Med 1995)

Practice Neurology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Neurology diagnoses

Ischemic StrokeHemorrhagic (Intracerebral) StrokeTransient Ischemic Attack (TIA)Subarachnoid Hemorrhage (SAH)Subdural Hematoma (SDH)Epidural Hematoma (EDH)Concussion / Mild Traumatic Brain InjuryMigraineTension-Type HeadacheCluster HeadacheSeizures and EpilepsyStatus EpilepticusMultiple SclerosisGuillain-Barré Syndrome

Differentials & related conditions

Hypothyroidism (Hashimoto Thyroiditis)Chronic Kidney Disease (CKD)

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.